Combining GLP-1 and SGLT2 drugs reduces heart attacks, strokes, and death more than either drug alone | Research

The takeaway

Meta-analysis shows GLP-1RA + SGLT2i combination therapy vs monotherapy significantly reduced MACE (HR 0.59), all-cause mortality (HR 0.57), MI, stroke, HF hospitalization, and renal events in T2D patients.

41% MACE reduction vs monotherapy
Combining GLP-1 and SGLT2 drugs provides dramatically better cardiovascular protection than either drug alone in type 2 diabetes

What the researchers found

RCTs: no interaction (p>0.05 all outcomes)—GLP-1RA benefits consistent with/without SGLT2i. Observational: combo vs SGLT2i mono: MACE HR 0.59, all-cause mortality HR 0.57, MI HR 0.73, stroke HR 0.72, HF HR 0.71. Combo vs GLP-1RA mono: CV mortality HR 0.35, all-cause mortality HR 0.59, renal HR 0.43.

Why it matters

This provides the strongest evidence to date that combining GLP-1 and SGLT2 drugs saves more lives and prevents more cardiovascular and kidney events than either drug alone—supporting dual therapy as a new standard for high-risk T2D patients.

How the study worked

Systematic search of MEDLINE/Embase. 4 post hoc RCT analyses + 10 observational studies. Random-effects meta-regression (RCTs) and meta-analysis (observational) for cardiorenal outcomes.

What this study cannot tell us

RCT evidence is from post hoc analyses, not dedicated combination trials. Observational data subject to confounding and selection bias. Heterogeneity across studies. No data on triple combination with finerenone.

How to read the evidence

Systematic review combining RCT post hoc analyses with observational data. Concordant evidence from both sources strengthens conclusions, though dedicated combination trials are needed.

When this study was published

Published in 2025.

The bigger picture

This meta-analysis supports a paradigm shift from sequential to early combination therapy in T2D cardiorenal management. The additive benefits suggest these drug classes work through complementary mechanisms that together provide substantially greater protection.

Questions still open

When should combination therapy be initiated—at diagnosis or after progression?
Are the benefits of combination consistent across different GLP-1 and SGLT2 agents?
Will dedicated prospective combination trials be conducted?

Common questions

Should I take both a GLP-1 drug and an SGLT2 inhibitor?

If you have type 2 diabetes with cardiovascular or kidney risk, this analysis strongly suggests that taking both provides substantially better protection than either alone—reducing heart attacks by 27%, strokes by 28%, and mortality by 43%. Discuss with your doctor whether dual therapy is right for you.

How do these drugs work differently to protect the heart and kidneys?

GLP-1 drugs primarily reduce atherosclerotic events (heart attacks, strokes) and provide metabolic benefits. SGLT2 inhibitors primarily reduce heart failure and kidney damage. Together, they address different aspects of cardiovascular-kidney risk, which is why combining them provides greater total protection.

Read the original research

Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis.

Cardiovascular diabetology, 24(1), 370

View on PubMed ↗Publisher’s paper ↗

Citation

Shokravi, Arveen; Seth, Jayant; Mancini, G B John. (2025). Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis.. Cardiovascular diabetology, 24(1), 370. https://doi.org/10.1186/s12933-025-02900-8